BSFA.LSE BSF Enterprise Plc

Healthcare Biotechnology London Exchange
0.0099 GBX
Close of Nov 3, 2026
0.5000 475.20
Market cap
GBX 2.01M
P/E
-
P/B
1.04x
ROE
-217.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is BSFA.LSE undervalued?

Graham number

The Graham number of BSF Enterprise Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BSF Enterprise Plc fundamental analysis

No fundamental analysis for BSF Enterprise Plc yet.

BSF Enterprise Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BSF Enterprise Plc

BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.

Full company profile